Supernus Pharmaceuticals SUPN Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements at other companies

Corebridge FinancialCRBG

-$388M-169%

Willis Towers WatsonWTW

$0—

Corebridge FinancialCRBG

$0+100%

Corebridge FinancialCRBG

$430M+183%

Minerals TechnologiesMTX

$0—

Corebridge FinancialCRBG

-$42M+74.5%

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.62B+62.8%

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's fair value measurement with unobservable inputs reconciliation recurring basis liability settlements.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's fair value measurement with unobservable inputs reconciliation recurring basis liability settlements?: Supernus Pharmaceuticals (SUPN) reported fair value measurement with unobservable inputs reconciliation recurring basis liability settlements of $0 in Q1 2026.